Navigation Links
Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
Date:4/1/2008

EMERYVILLE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that, effective April 1, 2008, Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar will be based at the Company's headquarters in Emeryville. Mr. Loar joins the company from Osteologix, where he has served as Chief Financial Officer since 2006.

"Matt has a proven track record as a chief financial officer, and we will look to his expertise to help guide our financial and business strategy," said Paul E. Freiman, President and Chief Executive Officer of Neurobiological Technologies. "His wealth of experience in helping to run several businesses combined with his knowledge of industry accounting requirements, SEC compliance and the biotech investment community will be real assets as our team continues to advance our strategic vision."

Mr. Loar is a Certified Public Accountant and has over twenty years experience in finance and accounting. Mr. Loar has a strong track record working with growing pharmaceutical and biotechnology companies, and has played a key role in several major corporate collaborations, successfully completing public and private equity financings and implementing the provisions of Sarbanes-Oxley Act at a public biotechnology company.

"NTI has a strong management team, a unique product development strategy, and tremendous potential for their phase 3 investigational drug, Viprinex(TM).

I look forward to becoming a key contributor to their future growth," said Mr. Loar. "NTI's efforts to develop new and improved central nervous system therapeutics are indeed exciting, and I'm anxious to start working with the other members of NTI's team to maximize the organization's overall potential."

Since the fall of 2006, Mr. Loar held the position of Chief Financial Officer at Osteologix, Inc. Prior to his tenure at Osteologix, he spent eleven years with Genelabs Technologies, Inc. where he held several positions, including Chief Financial Officer, Vice President of Finance and Controller. Earlier in his career, from 1991 through 1995, Mr. Loar was Corporate Accounting Manager for an international manufacturing company with approximately $500 million in annual product sales. From 1986 to 1991 he was audit manager with Coopers & Lybrand, a predecessor firm to PriceWaterhouseCoopers. Mr. Loar graduated from the University of California, Berkeley and is a member of the American Institute of CPAs. He is a member of Financial Executives International and for two years served as treasurer of their Silicon Valley Chapter.

As an inducement to his entering into employment with the Company, Mr. Loar was awarded an option in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) to purchase up to 150,000 shares of the Company's common stock outside of the Company's stockholder-approved equity incentive plans, at an exercise price per share equal to the fair market value of the Company's common stock on April 1, 2008. The inducement option, which will have a term of 10 years, will vest with respect to one-eighth of the underlying shares six months after the date of grant and then with respect to the remaining shares ratably over the next 42 months.

About Neurobiological Technologies

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline includes other drug candidates in early-stage development, including a first-of-its-kind drug for the treatment of Alzheimer's disease.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... ... ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event company in ... the world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category ... due to its new team building format, a way for teams to not only interact ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):